CompletedNCT00149734
Ondansetron and auditory processing during antipsychotic treatment for schizophrenia
About this title
Read the official source —Medication studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- DenverSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 8
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00149734
- Official title
Show the full official title
Atypical Antipsychotics and P50 Sensory Gating
Get this study by email
Recruitment & locations
CompletedDenver
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Did this study involve medication?
Yes. The study involved medication, including Ondansetron followed by placebo and Placebo followed by Ondansetron.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia